Clozapine, Chlorpromazine, and Placebo in Newly Hospitalized, Acutely Schizophrenic Patients: A Controlled, Double-Blind Comparison

Archives of General Psychiatry

Volumn 36, Issue 6, 1979, Pages 657-664

  Shopsin, Baron ^a   Klein, Helmfried ^a   Aaronsom, Michele ^a   Collora, Maria ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; APOMORPHINE; CHLORAL HYDRATE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; LOXAPINE; LOXAPINE SUCCINATE; PARALDEHYDE; PLACEBO; THIORIDAZINE;

ADVERSE DRUG REACTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMPARISON; EXTRAPYRAMIDAL SYMPTOM; HYPERSALIVATION; HYPOTENSION; MAJOR CLINICAL STUDY; METIAPINE; ORAL DRUG ADMINISTRATION; SCHIZOPHRENIA; SEDATION; TACHYCARDIA; THERAPY;

ACUTE DISEASE; ADULT; CHLORPROMAZINE; CLINICAL TRIALS; CLOZAPINE; COMPARATIVE STUDY; DIBENZAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HOSPITALS, PSYCHIATRIC; HUMAN; MALE; MIDDLE AGE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL ADJUSTMENT; UNITED STATES;

EID: 0018565672     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1979.01780060047005     Document Type: Article

References (42)

1. Janssen PAJ, Neimegeers CJE, Schellekens KHL: Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from aniaml data? Arzneim Forsch 15:104-117, 1965.
2. Carlsson A, Lindqvist M: Effect of chlorpromazine or haloperidol on formation of 3-methoxy-tyramine and normetanephrine in mouse brain. Acta Pharmacol 20:140-144, 1963.
3. Roos BE: Effect of certain tranquilizers on the level of homovanillic acid in the corpus striatum. J Pharm Pharmacol 17:820-821, 1965.
4. Anden NE, Roos BE, Werdinius B: Effects of chlorpromazine, haloperidol and reserpine on the level of phenolic acids in the rabbit corpus striatum. Life Sci 3:149-158, 1964.
5. Haase HJ: Uber Vorkommen und Deutung des psychomotorischen Parkinsonsyndrom bei Megaphen bzw. Largactil-Dauerbehandlung Nervenarzt 25:486-492, 1954.
6. Horn AS, Snyder SH: Chlorpromazine and dopamine: Conformational similarities that correlate with the antischizophrenic activity of phenothiazine drugs. Proc Natl Acad Sci USA 68:2325-2328, 1971.
7. Clement-Cormier YC, Kebabian JW, Petzold GL, et al: Dopaminesensitivity adenylate cyclase in mammalian brain: A possible site of action of antipsychotic drugs. Proc Nati Acad Sci USA 71:1113-1117, 1974.
8. Snyder SH, Greenberg D, Yamamura HI: Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31:58-61, 1974.
9. Haase HJ: Müglichkeiten und Grenzen der Psychopharmakotherapie mit Tranquilizern und Neuroleptika. Dtsch Med Wochenschr 88:505-514, 1963.
10. Haase HJ: Therapie mit Psychopharmaka und anderen psychotropen Medikamenten. Düsseldorf, Germany, Janssen GmbH, 1969.
11. Van Rossum JM, Janssen PAJ, Boissier JR, et al: Pharmacology. Mod Probl Pharmacopsychiatry 5:23-70, 1970.
12. Gross H, Langner E: Das Wirkungsprofil eines chemisch neuartigen Breitbandneuroleptikums der Dibenzodiazepingruppe. Wein Med Wochenschr 116:814-816, 1966.
13. DeMaio D: Preliminary clinical evaluation of a new neuroleptic agent HF-1854, in: The Present Status of Psychotropic Drugs: Pharmacological and Clinical Aspects. Amsterdam, Exerpta Medica Foundation, 1969, pp 485-488.
14. Berzewski H, Helmchen H, Hippius H, et al: Das klinische Wirkungsspektrum eines neuen Dibenzodiazepinderivates W-108/HF-1854: 8-Chlor11-(4′-methyl)-piperazino-5-dibenzo [b,e] [1,4] diazepin. Arzneim Forsch 19:495-496, 1969.
15. Stille G, Ackerman H, Lauener H, et al: The pharmacological properties of a potent neuroleptic compound from the dibenzodiazepine group. Int J Neuropharmacol 4:375-383, 1971.
16. Stille G, Lauener H, Eichenberger E: The pharmacology of 8-chloro11-(4′-methyl)-piperazino)-5H-dibenzo [b,e] [1,4] diazepine (clozapine). Farmaco [Prat] 26:603-625, 1971.
17. Ayd FJ: Clozapine: A unique new neuroleptic. Int Drug Ther Newsletter 9:5-12, 1974.
18. Matz R, Rick W, Oh D, et al: Clozapine: A potential antipsychotic agent without extrapyramidal manifestations. Cur Ther Res 7:687-695, 1974.
19. Shopsin B, Pearson E, Gershon Ṣ, et al: A controlled double-blind comparison between loxapine succinate and chlorpromazine in acute newly hospitalized schizophrenic patients. Curr Ther Res 14:739-748, 1972.
20. Clinical Investigators Manual, Clozapine. Hanover, NJ, Pharmaceutical Division Sandoz, Inc, 1976.
21. Angst J, Haenicke U, Padrutt A, et al: Ergebnisse eines Doppelblindversuches von HF-1854 (8-Chlor-11-(4 methyl-l-piperazinyl)-5H-dibeno (b,e) (1,4) diazepine). Vergleich Levomepromazin Pharmakopsychiat 4:192-200, 1971.
22. Gross H, Langner E, Pfolz H: Clozapin in der Langzeittherapie der Chronischen Schizophrenie. Arzneim Forsch 24:987-989, 1970.
23. Fisher-Cornelssen K, Ferner U, Steiner H: Multifokale Psychopharmakaprufung. Arzneim Forsch 24:1006-1007, 1974.
24. Nidkanen P, Achte K, Jaskari M, et al: Results of a comparative double-blind study with clozapine and chlorpromazine in the treatment of schizophrenic patients. Eripainos Psychiatria Fennica, 1974, pp 307-313.
25. Gerlach J, Koppelhus P, Helweg E, et al: Clozapine and haloperidol in a single-blind cross-over trial: Therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410-424, 1974.
26. Gerlach J, Munkvad I: Clozapine and haloperidol: Clinical and biochemical aspects in the treatment of schizophrenia. Nor Psykiatr Tidsskr 28:463, 1974.
27. Gerlach J, Thorsen K, Fog R: Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia 40:341-350, 1975.
28. Klein H, Aronson M, Shopsin B: Clozapine: Double-blind control trial in the treatment of acute schizophrenia. Psychopharmacol Bull 14:12-15, 1978.
29. Hippius H, Klein HE: Summary of the clinical aspects on treatment with clozapine (Leponex). Read before the Leponex Symposium, New York, Sept 30, 1974.
30. Blum AWW: Temperaturanstiege und Bluteiweis-veränderungen unter der Therapie mit Neuroleptika—unter besonderer Berücksichtigung des neuartigen Dibenzodiazepin-Derivates Clozapine (Wander). Verlag Weiner Med Akad, 1972, pp 113-119.
31. Gram LF: Bone-marrow depression following treatment with clozapine (Leponex). Vgeskr Laeg 138:1271-1273, 1976.
32. Griffith RW, Saameli K: Clozapine and agranulocytosis. Lancet 4:657, 1975.
33. Idanpaan-Heikkila J, Alhava E, Olkinuora M: Clozapine and agranulocytosis. Lancet 2:611, 1975.
34. Leucocytopenias and agranulocytosis during Leponex treatment, in Situation Report. Basel, Switzerland, Sandoz Ltd, 1976.
35. Stille G: Effect of single and repeated administration of clozapine on the metabolism of dopamine and noradrenaline in the brain of the rat. Eur J Pharmacol 27:180-190, 1974.
36. Miller RJ, Hiley CR: Antimuscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 248:495-497, 1974.
37. Stadler H, Loyd KG, Bartholini G: Dopaminergic inhibition of striatal cholinergic neurons; Synergistic blocking action of γ-butyrolactone and neuroleptic drugs. Arch Pharmacol Exp Pathol 283:129-134, 1974.
38. Bartholini G, Haefeli W, Jalfre M, et al: Effects of clozapine on cerebral catecholaminergic neurone systems. Br J Pharmacol 46:736-740, 1972.
39. Sedvall G, Nybäck H: Effect of clozapine and some other antipsychotic agents on synthesis and turnover of dopamine formed from 14C-tyrosine in mouse brain. Israel U Med Sci J 9:24-30, 1973.
40. Eichenberger E, Sayers AC, White TG: Clozapine and the dopamine hypothesis of schizophrenia: A critical appraisal. Phermakopsychiatr Neuropsychopharmakol 8:115-121, 1975.
41. Gruen P, Sachar E, Langer G, et al: Prolactin response to neuroleptics in normals and schizophrenics. Arch Gen Psychiatry 35:1222-1227, 1978.
42. Ackenheil M, Matussek N, Hippius H, et al: Sulpiride and the dopamine hypothesis of schizophrenia. Read before the International Group for the Study of Affective Disorders, Munich, Germany, June 24, 1976.